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Abstract
Background: Transurethral resection of the prostate (TURP) is considered the gold standard
for male lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia
(BPH). However, TURP may lead to sexual dysfunction and incontinence, and has a long
recovery period. Prostatic urethral lift (PUL) is a treatment option that may overcome these
limitations.
Objective: To compare PUL to TURPwith regard to LUTS improvement, recovery, worsening of
erectile and ejaculatory function, continence and safety (BPH6).
Design, setting, and participants: Prospective, randomized, controlled trial at 10 European
centers involving 80 men with BPH LUTS.
Intervention: PUL or TURP.
Outcome measurements and statistical analysis: The BPH6 responder endpoint assesses
symptom relief, quality of recovery, erectile function preservation, ejaculatory function preser-
vation, continence preservation, and safety. Noninferiority was evaluated using a one-sided
lower 95% conﬁdence limit for the difference between PUL and TURP performance.
Results and limitations: Preservation of ejaculation and quality of recovery were superior
with PUL (p < 0.01). Signiﬁcant symptom relief was achieved in both treatment arms. The
study demonstrated not only noninferiority but also superiority of PUL over TURP on the BPH6
endpoint. Study limitations were the small sample size and the inability to blind participants
to enrollment arm.
Conclusions: Assessment of individual BPH6 elements revealed that PULwas superior to TURP
with respect to quality of recovery and preservation of ejaculatory function. PUL was superior
to TURP according to the novel BPH6 responder endpoint, which needs to be validated in
future studies.
Patient summary: In this study, participants who underwent prostatic urethral lift responded
signiﬁcantly better than those who underwent transurethral resection of the prostate as
therapy for benign prostatic hyperplasia with regard to important aspects of quality of life.
Trial registration: ClinicalTrials.gov NCT01533038.
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Table 1 – Patient selection criteria
Inclusion criteria
 Willing to sign informed consent
 Male aged 50 yr
 International Prostate Symptom Score >12
 Qmax 15 ml/s for 125-ml voided volume
 Post-void residual volume <350 ml
 Prostate volume 60 cm3 on ultrasound
 Sexually active within 6 mo before the index procedure
 Sexual Health Inventory for Men score >6
 Positive response to MSHQ-EjD (excluding the response ‘‘Could not
ejaculate’’)
 Incontinence Severity Index score 4
Exclusion criteria
 Active urinary tract infection at time of treatment
 Bacterial prostatitis within 1 yr of the index procedure
 Cystolithiasis within 3 mo of the index procedure
 Obstructive median lobe, as assessed via ultrasound and cystoscopy
 Current urinary retention
 Urethral conditions that may prevent insertion of a rigid 20F cystoscope
 Previous TURP or laser procedure, pelvic surgery or irradiation
 Prostate-speciﬁc antigen 10 ng/l, history of prostate or bladder cancer
 Severe cardiac comorbidities
 Anticoagulants within 3 d of the index procedure (excluding up to
100 mg acetylsalicylic acid)
 Other medical condition or co-morbidity contraindicative for TURP or
PUL
 Unwilling to report sexual function
Qmax = peak ﬂow rate; MSHQ-EjD = Male Sexual Health Questionnaire for
Ejaculatory Dysfunction; TURP = transurethral resection of the prostate;
PUL = prostatic urethral lift.
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Male lower urinary tract symptoms (LUTS) secondary to
bladder outlet obstruction (BOO) as a result of benign
prostatic obstruction (BPO) are a quality of life (QoL) issue
estimated to affect 30% of men >50 yr of age, representing
26 million men in Europe [1]. Although symptom-
relieving therapies exist, men may be hesitant in seeking
invasive care because of the associated risks. In selecting
treatment options for one QoL issue, LUTS, it may be
important to consider other aspects of QoL. Studies that
investigated the extent to which LUTS severity influences
QoL indicate that the most important factors are often not
changes in symptoms but the preservation of continence
and sexual function [2–4]. In addition to potency, ejacula-
tory function has been found to significantly influence sex
life [5]. Patient satisfaction is also determined by return
to normal activity and perioperative complications [6].
This study introduces a new, comprehensive endpoint
referred to as BPH6 that reflects these patient-important
goals: (1) adequate relief from LUTS; (2) high-quality
recovery experience; (3) maintenance of erectile function;
(4) maintenance of ejaculatory function; (5) maintenance of
continence; and (6) avoidance of high-grade complications.
Transurethral resection of the prostate (TURP) is the
gold standard with regard to symptom relief and improve-
ments in urinary flow, but is associated with significant
morbidity and long-term complications including stricture
(7%), surgical revision (6%), significant urinary tract infection
(4%), bleeding requiring blood transfusion (3%), incontinence
(3%), transurethral resection syndrome (1%), erectile dys-
function (10%), and ejaculatory dysfunction (65%) [7,8]. Less
invasive techniques strive to offer a meaningful therapeutic
response with less morbidity than TURP. The prostatic
urethral lift (PUL) is a minimally invasive procedure that
yields effective treatment with little morbidity [9–16]. Here
we present 1-yr results from a prospective, randomized
trial comparing PUL to TURP in terms of the BPH6 endpoint.
We hypothesized that when evaluated using the BPH6
composite endpoint, PUL is not inferior to TURP as a
treatment option.
2. Patients and methods
2.1. Study protocol and procedure
A prospective, randomized, nonblinded study was conducted across
three European countries. Ethics committee approval was obtained at
each site (Clinicaltrials.gov NCT01533038). Eligible men were aged at
least 50 yr, were candidates for TURP, andwere enrolled by investigators
if they met the study criteria (Table 1). Parallel randomization was
conducted at a ratio of 1:1 at the time of the procedure, stratiﬁed by site,
and performed using permuted blocks of various sizes chosen at random
and concealed through a password-protected computer database.
PUL involves transurethral placement of small, permanent UroLift
implants to retract the lateral lobes of the prostate and reduce
obstruction [15]. Typically, multiple implants are placed to deobstruct
the prostatic urethra. Surgeon experience with PUL varied from zero to
20 procedures before enrollment, whereas each surgeon had extensive
prior experience with TURP. Licensed urologists trained and experiencedin TURP conducted TURP procedures in accordance with their own
normal standards and practices. A single surgeon at each site conducted
between two and 19 procedures using general (86%), spinal (13%), or
topical (1%, PUL only) anesthesia in the operating room. One site had two
surgeons, each of whom performed four or more procedures. Patients
were followed with visits at 2 wk and 1, 3, 6, and 12 mo.
2.2. Study endpoint and statistical methods
The BPH6 primary study endpoint is a composite of six elements that
assess overall outcome. The objectivewas to show that the success rate for
PUL is not inferior to TURP in terms of the composite endpoint at 12 mo.
Two modiﬁcations were made to the original element deﬁnitions to
increase the quality and relevance of the analysis. In the original endpoint
deﬁnition, the sexual function elements were assessed at a single time
point, 12mo. Because sexual activity can vary frommonth tomonth, both
elements were modiﬁed to instead assess sustained effects during 12mo.
In addition, the majority of patients reported a return to preoperative
activity by 1 mo on a separate questionnaire, yet scored >70 rather than
>80 on the visual analog scale (VAS). The threshold for quality of recovery
was thus lowered from80 to 70 to address this correlation. The ﬁnal BPH6
responder endpoint is achieved if a participantmeets all six of the criteria
as deﬁned in Table 2: LUTS relief, recovery experience, erectile function,
ejaculatory function, continence, and safety.
The study was powered to establish noninferiority of PUL to TURP for
noninferiority delta of 10% for the BPH6 primary endpoint. Performance
estimates from the literature predicted that power of 80% would
be achieved with enrollment of 62 participants, assuming the BPH6
success rate was 51% and 30% for PUL and TURP, respectively. Additional
participants were enrolled to account for potential loss to follow up.
Should noninferiority be achieved, superiority was to be tested with no
alpha inﬂation, since this follows the testingmethodology for hierarchical
closed-form hypotheses. A value of p < 0.05 was deﬁned as statistically
signiﬁcant. The success rates for the primary study endpoint were ﬁrst
Table 2 – The six elements of the final BPH6 responder endpoint
BPH6 element Assessment requirement Rationale
LUTS relief Reduction of 30% in IPSS at
12 mo compared to baseline
Analysis of large-scale randomized trials indicates that 30% IPSS improvement is a
suitable threshold for patient satisfaction and treatment acceptability [17]
Recovery experience QoR VAS 70 by 1 mo Postoperative return to normal activity is measured using a global QoR VAS (Fig. 1) with
signiﬁcant convergent validity with the QoR Score [18], a postoperative recovery outcome
with content and construct validity [19] suitable for ambulatory surgery [20]. The
threshold of 70% by 1 mo is chosen to reﬂect high-quality, rapid recovery
Erectile function Reduction of <6 points for SHIM
compared to baseline during
12-mo follow-up
SHIM is widely used to measure the severity of erectile dysfunction in clinical practice
[21]. and >5 points has been used as the minimum clinically meaningful change [22]
Ejaculatory function Response to MSHQ-EjD question
3 indicating emission of semen
during 12-mo follow-up
Absence of ejaculate has been quantiﬁed using the four-item MSHQ-EjD
[23]. Postoperative emission of semen is indicated by a ‘‘non-zero’’ response to the
volume item of the questionnaire
Continence preservation ISI score of 4 points at all
follow-up intervals
The ISI consists of two questions on the frequency and amount of urinary leakage [24] and
has been used in epidemiological surveys and clinical trials of LUTS treatment [2,25]. An
incontinence threshold of ISI >4 [25] corresponds to the threshold for severe incontinence
in the three-level index [24]
Safety No treatment-related adverse
event greater than grade I on the
Clavien-Dindo classiﬁcation
system at any time during the
procedure or follow up
The Clavien-Dindo classiﬁcation of surgical complications has been validated in many
ﬁelds including urology [26,27]. A threshold of grade II+ was selected to account for
events that might signiﬁcantly affect a patient’s postoperative course, such as those
requiring surgery, endoscopy, radiology, or supranormal pharmacology. If a patient
pursues secondary treatment, the failure to respond is captured in the effectiveness
element (#1) and not the safety element (#6); the patient is therefore censored from the
safety element analysis at all subsequent time points
LUTS = lower urinary tract symptoms; IPSS = International Prostate Symptom Score; QoR VAS = quality of recovery visual analog scale; SHIM = Sexual Health
Inventory for Men; MSHQ-EjD = Male Sexual Health Questionnaire for Ejaculatory Dysfunction; ISI = Incontinence Severity Index.
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x2 test. The exact method was used to establish 95% conﬁdence intervals
for the primary endpoint response.
Secondary analyses included comparison of treatment groups with
respect to International Prostate Symptom Score (IPSS), IPSS QoL, BPH
impact index (BPH II), peak ﬂow rate (Qmax), Male Sexual Health
Questionnaire for Ejaculatory Dysfunction (MSHQ-EjD), and post-void
residual volume (PVR). Changes from baseline for these measures were
compared across treatment groups at each follow-up visit using analysis
of covariance with the baseline score as a continuous covariate. The x2
test and Fisher’s exact test were used for categorical characteristics as
appropriate. The null hypothesis for pad use concerned the probability of
new pad use given BPH6 failure. All statistical analyses were performed
using SAS version 9.3 (SAS Institute, Cary, NC, USA) or StatXact (Cytel,
Cambridge, MA, USA).[(Fig._1)TD$FIG]
Fig. 1 – Single-item questionnaire using a vis3. Results
Between February 2012 and October 2013, 80 patients
(45 PUL, 35 TURP) were enrolled in a prospective, random-
ized, controlled study at ten European centers (Fig. 2). One
patient was excluded from the analysis for violation of the
active urinary retention exclusion criterion. Participants
were well matched between the study arms, with no
statistically significant differences in baseline parameters
except for the MSHQ-EjD function score (Table 3). After
adjusting for any difference in baseline parameters
between the enrollment arms, the conclusions for the
primary endpoint and the sexual function analyses remained
unchanged.ual analog scale for quality of recovery.
Table 3 – Baseline characteristics and procedure details for study participants
Characteristics PUL (n = 44) a TURP (n = 35)
Mean SD Range n Mean SD Range n
Age (yr) 63 6.8 50–84 44 65 6.4 51–78 35
Prostate volume (cm3) 38 12 16–59 44 41 13 17–68 35
Prostate length (mm) 46 6.4 24–56 43 47 5.8 37–60 34
Prostate-speciﬁc antigen (ng/ml) 2.4 1.8 0.4–8.2 43 2.6 2.1 0.3–8.6 33
International Prostate Symptom Score 22 5.7 12–33 44 23 5.9 13–34 35
Qmax (ml/s)
b 9.2 3.5 3–15 39 9.5 3.2 3–15 32
Post-void residual volume (ml) 86 72 0–344 44 102 87 0–328 35
Sexual Health Inventory for Men 20 4.9 7–25 44 18 5.5 7–25 35
MSHQ-EjD function 11 2.7 4–15 44 9 2.3 4–13 35
MSHQ-EjD bother 1.7 1.8 0–5.0 44 2.0 1.5 0–4.0 35
Anesthesia time (min) 55 17 25–92 44 71 20 44–134 35
PUL implants (n) 4.7 1.1 2–6 44 NA
Time to discharge (d) 1.0 0.9 0–4 44 1.9 1.0 1–4 35
Return to preoperative activity level (d) 11 19 0–127 43 17 19 2–92 32
PUL = prostatic urethral lift; TURP = transurethral resection of the prostate; Qmax = peak ﬂow rate; MSHQ-EjD = Male Sexual Health Questionnaire for
Ejaculatory Dysfunction; NA = not applicable.
a PUL participant 9-003 was excluded for protocol deviation (violation of exclusion criterion).
b Qmax is not calculated for voided volume <125 ml.
[(Fig._2)TD$FIG]
Analysis
PUL retreatment (n = 2)
Laser (n = 1)
Protocol deviation (n = 1)
Laser (n = 1)
Botox (n = 1)
Withdrawn (n = 1)
Underwent PUL (n = 45)Underwent TURP
(12 unipolar + 23 bipolar = 35 total)
Allocated to TURP (n = 45) Allocated to PUL (n = 46)
Underwent randomization
(n = 91)
Allocation
Enrollment
Analyzed for primary endpoint (n = 35) Analyzed for primary endpoint (n = 44)
Declined treatment
(n = 10)
Declined treatment
(n = 1)
Follow-up
Fig. 2 – CONSORT diagram of the BPH6 study including randomization, treatment, and follow-up of subjects. TURP=transurethral resection of the
prostate; PUL=prostatic urethral lift.
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TURP patients (Fig. 3). The proportion of patients achieving
the BPH6 recovery endpoint by 1 mo was 82% in the PUL
group, which was significantly better than the 53% in the
TURP group (p = 0.008). With the original threshold, 57%
PUL compared to 32% TURP patients achieved the recovery
endpoint. Furthermore, 74% of the TURP group had a
catheter formore than 24 h, compared to just 45% of the PULgroup (p = 0.01). The average number of days to discharge
was significantly lower (1.0 vs 1.9 d) and the return to
preoperative activity levels was significantly faster (11 vs
17 d) for PUL than for TURP patients (Table 3).
Significant improvements in IPSS, IPSS QoL, BPH II, and
Qmax were observed in both arms over time (Fig. 4, Table 4).
IPSS, Qmax, and PVR were better after TURP than after PUL
(p < 0.05, Fig. 4).
[(Fig._3)TD$FIG]
Fig. 3 – Percentage of subjects reporting I70% on the visual analog scale
for quality of recovery (QoR VAS) after prostatic urethral lift PUL and
TURP treatment. The 95% confidence intervals were calculated using the
Wilson method. * Significant difference between enrollment arms
(p < 0.05).
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groups as measured by SHIM scores (Fig. 4, Table 4).
Furthermore, the vast majority of participants achieved the
BPH6 erectile function responder endpoint, with only one
[(Fig._4)TD$FIG]Fig. 4 – Outcome following treatment with PUL or TURP measured in terms of
(QoL) index, (C) Benign Prostatic Hyperplasia Impact Index (BPH II), (D) peak f
12 months. Values are plotted as the mean with 95% confidence interval. * SigPUL (2.6%) and two TURP (6.1%) patients experiencing a
consistent drop in SHIM score after the procedure.
Regarding ejaculatory function, the PUL group experi-
enced an improvement in average ejaculatory score (MSHQ-
EjD) from baseline (p = 0.03), but the TURP group suffered
from a significant decline (p < 0.0001; Fig. 4, Table 4). For
the BPH6 ejaculatory assessment, the response for the PUL
group was 100%, significantly better than the 60.6%
response for the TURP group (p < 0.0001).
Continence preservation was comparable between the
groups, and no patient experienced new-onset stress or
sphincter incontinence. Of the participants who failed the
BPH6 continence element (six PUL and eight TURP patients
had ISI > 4 at any time), none (0/6, 0%) of the PUL patients
reported new-onset pad use, whereas six TURP patients (6/8,
75%) reported that they required pads after TURP (superior
PUL performance, p = 0.01).
The proportion of participants who met the original
BPH6 primary endpoint was 34.9% for the PUL group
and 8.6% for the TURP group (noninferiority p = 0.0002,
superiority p = 0.006). The refined BPH6 primary endpoint
was also met by 52.3% of PUL and 20.0% of TURP patients(A) International Prostate Symptom Score (IPSS), (B) IPSS quality of life
low rate (Qmax), (E) SHIM, and (F) MSHQ-EjD function through
nificant difference between the enrollment arms (p < 0.05).
Table 4 – Paired outcome measures following PUL or TURP
2 wk 1 mo 3 mo 6 mo 12 mo
PUL TURP PUL TURP PUL TURP PUL TURP PUL TURP
IPSS
n (paired) 42 34 44 33 42 34 40 33 41 32
BL, mean (SD) 21.9 (5.7) 22.6 (6.0) 22.1 (5.7) 22.8 (5.8) 22.3 (5.8) 22.6 (6.0) 22.2 (5.7) 22.6 (6.0) 22.0 (5.6) 22.8 (5.9)
FU, mean (SD) 14.6 (7.7) 15.7 (7.3) 10.5 (7.6) 12.9 (5.9) 10.5 (7.4) 10.8 (8.4) 9.2 (7.5) 8.0 (7.2) 10.7 (8.1) 7.3 (6.3)
D, mean (SD)
D, Q1, median, Q3
–7.3 (9.4)
–15.0, –6.5, 0.0
–6.8 (8.8)
–14.0, –5.0, 1.0
–11.6 (9.3)
–17.5, –12.0, –5.5
–10.0 (7.9)
–15.0, –10.0, –4.0
–11.7 (8.5)
–17.0, –11.0, –6.0
–11.8 (9.5)
–20.0, –13.0, –5.0
–13.0 (8.1)
–17.0, –13.0, –8.5
–14.6 (8.5)
–20.0, –13.0, –9.0
–11.4 (8.4)
–18.0, –10.0, –7.0
–15.4 (6.8)
–20.0, –14.5, –10.5
DD, mean (95% CI) 0.5 (–3.7, 4.7) 1.6 (–2.4, 5.7) –0.1 (–4.2, 4.1) –1.6 (–5.5, 2.3) –4.0 (–7.7, –0.4)
p value 0.8 0.3 1.0 0.4 0.02
IPSS QoL
n (paired) 43 34 44 33 43 34 40 33 40 32
BL, mean (SD) 4.7 (1.1) 4.8 (1.2) 4.6 (1.1) 4.8 (1.2) 4.7 (1.1) 4.8 (1.2) 4.7 (1.1) 4.7 (1.2) 4.7 (1.0) 4.6 (1.2)
FU, mean (SD) 3.0 (1.9) 3.7 (1.7) 2.2 (1.8) 3.0 (1.9) 2.1 (1.5) 2.4 (2.0) 1.9 (1.6) 1.8 (1.7) 1.9 (1.6) 1.5 (1.5)
D, mean (SD)
D, Q1, median, Q3
–1.7 (2.3)
–3.0, –2.0, 0.0
–1.0 (1.5)
–2.0, –1.0, 0.0
–2.5 (2.0)
–4.0, –2.5, –1.0
–1.8 (1.9)
–3.0, –2.0, 0.0
–2.6 (1.7)
–4.0, –2.0, –2.0
–2.4 (2.0)
–4.0, –3.0, –1.0
–2.8 (1.6)
–4.0, –3.0, –2.0
–2.9 (1.9)
–4.0, –3.0, –2.0
–2.8 (1.8)
–4.0, –3.0, –1.0
–3.1 (1.6)
–4.0, –3.0, –2.0
DD, mean (95% CI)
p value
0.7 (–0.2, 1.6)
0.1
0.7 (–0.2, 1.6)
0.1
0.3 (–0.6, 1.1)
0.5
–0.1 (–0.9, 0.7)
0.8
–0.3 (–1.1, 0.5)
0.4
BPH II
n (paired) 43 32 43 32 42 33 40 32 40 30
BL, mean (SD) 7.3 (2.5) 7.2 (3.0) 7.3 (2.5) 7.3 (3.1) 7.4 (2.4) 7.3 (3.1) 7.5 (2.4) 7.2 (3.1) 7.3 (2.4) 7.0 (3.1)
FU, mean (SD) 6.3 (3.3) 7.0 (3.1) 4.0 (3.1) 5.3 (3.0) 2.6 (2.8) 3.8 (3.4) 2.3 (2.5) 2.2 (2.5) 2.3 (2.8) 1.8 (2.6)
D, mean (SD)
D, Q1, median, Q3
–1.0 (4.3)
–5.0, 0.0, 2.0
–0.2 (3.7)
–3.0, 0.0, 2.5
–3.4 (4.3)
–7.0, –3.0, –1.0
–2.0 (3.6)
–4.5, –2.0, 1.0
–4.8 (3.6)
–7.0, –5.0, –3.0
–3.4 (3.5)
–5.0, –3.0, –1.0
–5.2 (2.9)
–7.0, –5.0, –4.0
–5.0 (3.3)
–7.0, –5.0, –3.0
–5.0 (3.7)
–7.0, –5.0, –3.5
–5.2 (3.2)
–6.0, –5.5, –3.0
DD, mean (95% CI)
p value
0.8 (–1.1, 2.7)
0.3
1.4 (–0.5, 3.3)
0.06
1.4 (–0.3, 3.0)
0.05
0.2 (–1.3, 1.7)
0.7
–0.2 (–1.9, 1.5)
0.8
Qmax
n (paired) 33 21 33 27 32 29
BL, mean (SD) 9.4 (3.5) 9.2 (3.2) 9.6 (3.4) 9.4 (3.2) 9.6 (3.5) 9.5 (3.3)
FU, mean (SD) 13.6 (5.3) 22.6 (9.0) 13.5 (5.5) 19.0 (8.8) 13.6 (5.5) 23.2 (10.5)
D, mean (SD)
D, Q1, median, Q3
4.2 (5.0),
1.0, 4.0, 7.0
13.4 (9.9)
6.0, 11.0, 17.0
3.8 (5.2)
2.0, 3.0, 6.0
9.6 (9.2)
2.0, 8.0, 19.0
4.0 (4.8)
0.5, 3.0, 7.5
13.7 (10.4)
6.0, 11.0, 18.0
DD, mean (95% CI)
p value
9.2 (5.1, 13.3)
<0.0001
5.8 (2.0, 9.6)
0.003
9.7 (5.6, 13.7)
<0.0001
PVR
n (paired) 39 32 40 31 41 32
BL, mean (SD) 87.6 (74.1) 98.6 (84.9) 85.5 (73.4) 100.5 (85.7) 86.3 (73.2) 103.5 (89.7)
FU, mean (SD) 77.3 (74.4) 47.6 (48.7) 80.7 (91.0) 46.2 (49.1) 93.7 (156.5) 33.6 (38.6)
D, mean (SD)
D, Q1, median, Q3
–10.3 (56.2)
–43.0, –3.0, 21.0
–51.0 (78.7)
–96.0, –40.5, 4.0
–4.8 (70.7)
–33.5, –1.0, 26.5
–54.2 (84.6)
–121.0, –34.0, 0.0
7.4 (115.2)
–28.0, 2.0, 20.0
–70.0 (79.0)
–121.5, –52.0, –10.0
DD, mean (95% CI)
p value
–40.6 (–72.6, –8.6)
0.002
–49.4 (–86.2, –12.6)
0.003
–77.4 (–124.9, –29.8)
0.002
SHIM
n (paired) 36 20 38 27 34 30 32 27
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E U R O P E AN URO L OGY 6 8 ( 2 0 1 5 ) 6 4 3 – 6 5 2 649(noninferiority p < 0.0001; superiority p = 0.005; Table 5).
At each follow-up interval, the responder rate was signifi-
cantly higher for PUL than for TURP patients (p = 0.0002–
0.006).
An independent external clinical events committee
comprising three board-certified urologists who were
blinded to the enrollment arm adjudicated on adverse
events. Medical history caused unblinding for 6% of events.
All adverse events classified as treatment-related were
assigned Clavien-Dindo grades according to predetermined
definitions (Table 6). Reintervention for failure to cure
occurred in 6.8% (3/44) of PUL and 5.7% (2/35) of TURP
patients (not significant; Table 7). No subject in either study
arm started taking an alpha blocker or 5 alpha reductase
inhibitor. PUL did not cause any adverse events that required
surgical intervention or revision (0%). Two patients (6%) in
the TURP group required surgical intervention for adverse
events, a perioperative secondary hemorrhage that required
revision and transurethral hemostasis, and an unpassable
urethral stricture that requiredurethrotomy3moafterTURP.
Furthermore, PUL patients experienced fewer treatment-
related infections (7%) than TURP patients (14%; p = 0.46).
4. Discussion
The BPH6 study is the first prospective, randomized
trial comparing PUL with TURP. The PUL procedure not only
met the primary study endpoint of noninferiority but also
demonstrated superiority compared to TURP with regard to
the BPH6 primary endpoint. Analysis of BPH6 element
endpoints demonstrated that TURPwas superior in reducing
IPSS (p = 0.05), whereas PUL was superior for quality of
recovery (p = 0.008) and preservation of ejaculatory function
(p < 0.0001). No significant differences were observed for
erectile dysfunction, incontinence, or grade II+ adverse
events; this may be a result of insufficient study power for
detection of differences in these elements of the BPH6.
Both study procedures effectively mitigated LUTS. At
12mo, PUL yielded an average decrease of 11.4  8.4 in IPSS,
consistent with previous studies [8–15]. The IPSS improve-
ment after TURP (15.4  6.8) was also as predicted [7,27].
These results, among others, indicate that both PUL and TURP
were performed using acceptable techniques.
One objective of a less invasive procedure is to improve
surgical recovery. The recovery period after TURP can last
from weeks to months, and may be disruptive for patients
and their families [28]. To the best of our knowledge, this
is the first study to quantify recovery experience after TURP
on a visual analog scale, and it gives a powerful indication
of patient experiences. The number of participants who
experienced the BPH6 definition of high-quality recovery
(VAS 70% by 1 mo) was greater for PUL than for TURP
(82% vs 53%, p = 0.008). Figure 3 gives a temporal view of
recovery after PUL and TURP. It is evident that TURP patients
required 6–12 mo to recover to the level reached by PUL
patients by 3 mo.
Iatrogenic sexual dysfunction plays a role in BPH
treatment,whethermedical or surgical. Clinical study results
have varied widely owing to myriad instruments and
Table 5 – BPH6 primary outcome: summary of response rates for the BPH6 endpoint and the six individual elements at 12 mo
Response (%) p value Difference, % (95% CI)
PUL TURP
Primary BPH6 endpoint 52 20 0.005 32 (10, 51)
LUTS element (IPSS reduction 30%) 73 91 0.05 –18 (–36, 0.72)
Recovery element (VAS 70% at 1 mo) 82 53 0.008 29 (6.0, 49)
Erectile function element (SHIM reduction <6) 97 94 0.6 3 (–8.6, 18)
Ejaculatory function (MSHQ-EjD #3 not zero) 100 61 <0.0001 39 (23, 58)
Continence (ISI <5) 85 75 0.4 10 (–9.0, 30)
Safety element (no Clavien-Dindo grade II+) 93 79 0.1 14 (–2.3, 32)
PUL = prostatic urethral lift; TURP = transurethral resection of the prostate; LUTS = lower urinary tract symptoms; CI = conﬁdence interval; IPSS = International
Prostate Symptom Score; VAS = visual analog scale; SHIM = Sexual Health Inventory for Men; MSHQ-EjD = Male Sexual Health Questionnaire for Ejaculatory
Dysfunction; ISI = Incontinence Severity Index.
Table 6 – Treatment-related AEs after PUL and TURP stratified by Clavien-Dindo classification grade
AEs PUL (n = 44) TURP (n = 35) p value
AEs Patients, AEs Patients,
(n) n (%) (n) n (%)
Clavien-Dindo grade 1
Bleeding 17 17 (39) 20 20 (57) 0.1
Irritative symptoms, pain, or discomfort 34 23 (52) 39 21 (60) 0.5
Urinary incontinence 1 1 (2) 6 6 (17) 0.04
Urinary retention 4 4 (9) 0 0 (0) 0.1
Erectile dysfunction 0 0 (0) 3 3 (9) 0.08
Retrograde ejaculation 0 0 (0) 7 7 (20) 0.002
Other 4 4 (9) 4 3 (9) >0.9
Total 60 30 (68) 79 26 (74) 0.6
Clavien-Dindo grade 2
Urinary tract infection 3 3 (7) 3 2 (6) >0.9
Epididymitis 0 0 (0) 2 2 (6) 0.2
Total 3 3 (7) 5 4 (11) 0.7
Clavien-Dindo grade 3a
Total 0 0 (0) 0 0 (0)
Clavien-Dindo grade 3b
Bleeding 1 1 (2) 2 2 (6) 0.6
Stricture (meatal, urethral, bladder neck) 0 0 (0) 1 1 (3) 0.4
Secondary treatment (TURP, laser, PUL, or Botox) 3 3 (7) 2 2 (6) >0.9
Total 4 4 (9) 5 5 (14) 0.5
AE = adverse event; PUL = prostatic urethral lift; TURP = transurethral resection of the prostate.
Table 7 – Reintervention (n = 8) following treatment with PUL (n = 44) or TURP (n = 35) at early (=30 d) and intermediate (>30–365 d) follow-
up
Adverse event Intervention PUL TURP p value a
Early (30 d)
Bleeding (n) Surgical revision 0 1
Bleeding/bladder tamponade (n) Evacuation 0 1
Total, n (%) 0 (0) 2 (6) 0.2
Delayed (>30–365 d)
Urethral stricture Urethrotomy 0 1
Return of LUTS/dissatisfaction Secondary treatment 3 2
Total, n (%) 3 (7) 3 (9) >0.9
Total early + delayed, n (%) 3 (7) 5 (14) 0.5
PUL = prostatic urethral lift; TURP = transurethral resection of the prostate.
a Fisher’s exact test.
E U RO P E AN URO LOG Y 6 8 ( 2 0 1 5 ) 6 4 3 – 6 5 2650reporting schemes. In this study, erectile functionwas largely
preserved in both treatment arms, as evidenced by the
stability of SHIM scores and the BPH6 erectile function
element. PULpatientshada superior experience compared to
TURP patients with respect to ejaculatory function: both theMSHQ-EjD scores and theBPH6ejaculatory function element
were significantly greater for the PUL group. The sexual
function SHIM and MSHQ results for the PUL group are
consistentwith previous studies [29,30]. The GOLIATH study
reported higher rates of de novo retrograde ejaculation in
E U RO P E AN URO L OGY 6 8 ( 2 0 1 5 ) 6 4 3 – 6 5 2 651TURP patients (84/133 = 63%) [27]. The lower than expected
rate of retrograde ejaculation for TURP patients in this study
may be because of differences in assessment technique.
The occurrence of de novo urge incontinence after BPH
therapy is not well characterized in the literature. Fewer PUL
thanTURPpatients crossed theBPH6 incontinence threshold,
but the difference was not statistically significant. Interest-
ingly, among those who failed BPH6 for incontinence, the
majority of the TURP patients (6/8, 75%) required pads,
compared to 0% of the PUL patients.
Although the results for the BPH6 safety element were
better for the PUL than for the TURP group, the difference
was not significant. Infections treated with medication
occurred more often after TURP, although the difference
was not significant. Failure to cure leading to secondary
treatment was considered to be a grade II+ adverse event by
the clinical events committee, and occurred at a comparable
rate in both arms. There were no related adverse events in
the PUL group that required surgical intervention; ure-
throtomy and revision/transurethral hemostasis for sec-
ondary hemorrhage occurred in the TURP group.
While the study size was sufficiently powered to address
the primary endpoint, it was not powered to ensure that the
sample sizewas sufficient todetectmeaningful differences in
secondary endpoints. Selection bias was minimized through
randomization and the development of patient enrollment
materials presenting a balanced view of the procedures.
Blinding was not achievable and enrollment was limited
because of the nature of randomization between disparate
therapies. After randomization, some subjects withdrew
from the study before index treatment (Fig. 2). Another
limitation is the 1 yr of follow-up, as durability would be
more fully assessed with data for 2 yr. It is important, as
with all clinical studies, to apply the conclusions to the
specific population studied, with a particular emphasis on
sexually active men.
5. Conclusions
This study provides the first randomized comparison of PUL
andTURP inmen suffering fromLUTS secondary toBPH. Both
PUL and TURP groups achieved significant symptom relief
compared tobaseline,with a superior symptomrelief rate for
TURP. PUL was superior to TURP in terms of quality of
recovery and preservation of ejaculatory function. Although
designed to detect noninferiority, the study demonstrated
superiority of PUL over TURP in terms of the new BPH6
responder endpoint.
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